1. Home
  2. ISRL vs IMA Comparison

ISRL vs IMA Comparison

Compare ISRL & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ISRL
  • IMA
  • Stock Information
  • Founded
  • ISRL 2021
  • IMA 2019
  • Country
  • ISRL United States
  • IMA United States
  • Employees
  • ISRL N/A
  • IMA N/A
  • Industry
  • ISRL Blank Checks
  • IMA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ISRL Finance
  • IMA Health Care
  • Exchange
  • ISRL Nasdaq
  • IMA Nasdaq
  • Market Cap
  • ISRL 79.3M
  • IMA 92.2M
  • IPO Year
  • ISRL 2023
  • IMA N/A
  • Fundamental
  • Price
  • ISRL $12.35
  • IMA $8.34
  • Analyst Decision
  • ISRL
  • IMA Buy
  • Analyst Count
  • ISRL 0
  • IMA 1
  • Target Price
  • ISRL N/A
  • IMA $30.00
  • AVG Volume (30 Days)
  • ISRL 1.6K
  • IMA 65.8K
  • Earning Date
  • ISRL 01-01-0001
  • IMA 11-13-2025
  • Dividend Yield
  • ISRL N/A
  • IMA N/A
  • EPS Growth
  • ISRL N/A
  • IMA N/A
  • EPS
  • ISRL 0.14
  • IMA N/A
  • Revenue
  • ISRL N/A
  • IMA $4,300,000.00
  • Revenue This Year
  • ISRL N/A
  • IMA N/A
  • Revenue Next Year
  • ISRL N/A
  • IMA N/A
  • P/E Ratio
  • ISRL $91.70
  • IMA N/A
  • Revenue Growth
  • ISRL N/A
  • IMA N/A
  • 52 Week Low
  • ISRL $11.22
  • IMA $7.24
  • 52 Week High
  • ISRL $14.00
  • IMA $23.28
  • Technical
  • Relative Strength Index (RSI)
  • ISRL 46.89
  • IMA N/A
  • Support Level
  • ISRL $12.20
  • IMA N/A
  • Resistance Level
  • ISRL $12.49
  • IMA N/A
  • Average True Range (ATR)
  • ISRL 0.07
  • IMA 0.00
  • MACD
  • ISRL -0.00
  • IMA 0.00
  • Stochastic Oscillator
  • ISRL 50.00
  • IMA 0.00

About ISRL Israel Acquisitions Corp

Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About IMA ImageneBio Inc. Common Stock

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Share on Social Networks: